摘要
目的了解同一地区不同年份CA16基因变异状况。方法在同一地区用同一方法分离CA16;随机抽取第一代细胞分离到的病毒株,测定VPl区基因序列,应用DNAstar和DNAman分子生物学软件对VPl基因进行分析比较。结果在2008年一2011年从104份标本中分离到47株CA16,病毒分离阳性率为45.2%;4年来,8株CA16核苷酸同源性为90.3%-100.0%,其中2010年分离的二株病毒核苷酸同源性为90.3%;8株CA16氨基酸同源性为97.9%-100.0%。结论由于在同一地区不同时间分离的CA16基因存在较大差异,因此选择CA16疫苗株时,应进行各种基因型及同一基因亚型中氨基酸变异较大毒株的交叉保护试验。
Objective To study the variation of CA16 gene during different years in one area. Methods CA16 was isolated from HFMD patients with the same method in the same area ; Then 8 viral isolates of the first - generation cell were randomly se- lected to determine the genetic sequence of VP1 region. DNAstar and DNAman were employed to analyze and compare theVP1 gene of the 8 isolates. Results Forty - seven CA16 strains were isolated from 104 specimens between 2008 and 2011, the posi- tive rate of virus isolation was 45.2%. In the 4 consecutive years, the nucleotide homology of 8 CA16 strains was between 90.3% and 100.0% , that of 2 CA16 isolates in 2010 was 90.3%, while the amino acid homology of the 8 CA16 iso]ates was between 97.9% and 100.0%. Conclusion As a result of the big diversity of CA16 gene at different times in one area, the cross -protection trial should be done in viral strains concerning different genotypes and big amino acid variation in the same subgenotype when selecting CA16 vaccine strain.
出处
《中国卫生检验杂志》
北大核心
2014年第3期316-318,共3页
Chinese Journal of Health Laboratory Technology